ArticleCancer medicine2015
Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance.
Article in Cancer medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Second edition ICCR dataset for testicular germ cell tumours: a reporting guide for histopathological diagnosis of orchiectomy specimens.Histopathology · 2026Review
- Assessment of new prognostic risk models for recurrence in patients with clinical stage I seminoma.BJU international · 2026Article
- Follow-up of non-palpable testicular incidentalomas under 1 cm: does growth rate differentiate malignant and non-malignant lesions?European radiology · 2025Observational
- The post-orchiectomy systemic inflammatory index is associated with tumor characteristics in clinical stage I germ cell tumors.Frontiers in oncology · 2025Article
- Current and Evolving Biomarkers in the Diagnosis and Management of Testicular Germ Cell Tumors.Journal of clinical medicine · 2024Review
- A novel T1a/b classification for testicular cancer: not only seminoma.Translational andrology and urology · 2024Article
- Multifocality in Testicular Cancer: Clinicopathological Correlations and Prognostic Implications.Life (Basel, Switzerland) · 2024Article
- SPTBN1 Mediates the Cytoplasmic Constraint of PTTG1, Impairing Its Oncogenic Activity in Human Seminoma.International journal of molecular sciences · 2023Article
- Outcomes of surveillance versus adjuvant treatment for patients with stage-I seminoma: a single-center experience.World journal of urology · 2023Article
- Spermatocytic Tumor: A Review.International journal of molecular sciences · 2023Review
- Diagnosis and treatment of primary seminoma of the prostate: A case report and review of literature.World journal of clinical cases · 2023Article
- Clinical features and prognostic factors in patients diagnosed with lymphovascular invasion of testicular germ-cell tumors: Analysis based on the SEER database.Frontiers in oncology · 2023Article
- Total embedding of spermatic cord and hilar soft tissue in orchiectomy for seminoma: does the extensive sampling improve pathologic risk factors?Virchows Archiv : an international journal of pathology · 2022Article
- Biomarkers of disease recurrence in stage I testicular germ cell tumours.Nature reviews. Urology · 2022Review
- Canadian Urological Association consensus guideline: Management of testicular germ cell cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Treatment options in stage I seminoma.Oncology research · 2022Review
- A Machine Learning Algorithm for Predicting the Risk of Developing to M1b Stage of Patients With Germ Cell Testicular Cancer.Frontiers in public health · 2022Article
- Article
- Narrative review of developing new biomarkers for decision making in advanced testis cancer.Translational andrology and urology · 2021Review
- [non-metastasised clincial stage I testicular germ cell tumours : Patient information, suitability and limitations of surveillance].Der Urologe. Ausg. A · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A prognostic model for relapse risk in stage I seminoma managed by surveillance after orchiectomy has been developed but has not been independently validated. Individual data on 685 stage I seminoma surveillance patients managed between 1998 and 2005 at three cancer centers were retrospectively analyzed. Variables including age and pathology of the primary tumor: small vessel invasion, tumor size, and invasion of rete testis were analyzed. Specifically median tumor size and rete testis invasion was tested to evaluate the performance of the published model. Median follow-up was 3.85 years (0.1-10.29), 88 patients relapsed and 5-year relapse-free rate was 85%. In univariate analysis, median tumor size (<3 cm vs. ≥3 cm) was associated with increased risk of relapse but rete testis invasion was not, nor was age and small vessel invasion. In multivariable analysis, tumor size above median (cutpoint of 3 cm) was a predictor for relapse, HR 1.87 (95% CI 1.15, 3.06), whereas rete testis invasion HR 1.36, (95% CI 0.81, 2.28) was not statistically significant. The 3-year relapse risk based on the primary tumor size alone increased from 9% for 1 cm primary tumor to 26% for 8 cm tumor. A clinically useful, highly discriminating prognostic model remains elusive in stage I seminoma surveillance as we were unable to validate the previously developed model. However, primary tumor size retained prognostic importance and a scale of relapse risk based on the unit increment of tumor size was developed to help guide patients and clinicians in decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.